Addiction Medicine Learning Series: Meeting the DEA Requirement of the MATE Act

Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003 Feb 22;361(9358):662-8. doi: 10.1016/S0140-6736(03)12600-1. PMID: 12606177.

Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009 Dec;37(4):426-30. doi: 10.1016/j.jsat.2009.05.003. Epub 2009 Jun 23. PMID: 19553061.

Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine Treatment Divide by Race/Ethnicity and Payment. JAMA Psychiatry. 2019 Sep 1;76(9):979-981. doi: 10.1001/jamapsychiatry.2019.0876. PMID: 31066881; PMCID: PMC6506898.

Roy PJ, Choi S, Bernstein E, Walley AY. Appointment wait-times and arrival for patients at a low-barrier access addiction clinic. J Subst Abuse Treat. 2020 Jul;114:108011. doi: 10.1016/j.jsat.2020.108011. Epub 2020 Apr 22. PMID: 32527508.

Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. JAMA Netw Open. 2019 Jun 5;2(6):e196373. doi: 10.1001/jamanetworkopen.2019.6373. PMID: 31251376; PMCID: PMC6604101.

Jakubowski A, Fox A. Defining Low-threshold Buprenorphine Treatment. J Addict Med. 2020 Mar/Apr;14(2):95-98. doi: 10.1097/ADM.0000000000000555. PMID: 31567596; PMCID: PMC7075734.

Eibl JK, Gauthier G, Pellegrini D, Daiter J, Varenbut M, Hogenbirk JC, Marsh DC. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 2017 Jul 1;176:133-138. doi: 10.1016/j.drugalcdep.2017.01.048. Epub 2017 May 17. PMID: 28535455.

Srivastava A, Clarke S, Hardy K, Kahan M. Facilitating rapid access to addiction treatment: a randomized controlled trial. Addict Sci Clin Pract. 2021 May 25;16(1):34. doi: 10.1186/s13722-021-00240-y. PMID: 34034821; PMCID: PMC8152083.

Evans E, Li L, Min J, Huang D, Urada D, Liu L, Hser YI, Nosyk B. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015 Jun;110(6):996-1005. doi: 10.1111/add.12863. Epub 2015 Mar 15. PMID: 25644938; PMCID: PMC4452110.

Dupouy J, Palmaro A, Fatséas M, Auriacombe M, Micallef J, Oustric S, Lapeyre-Mestre M. Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study. Ann Fam Med. 2017 Jul;15(4):355-358. doi: 10.1370/afm.2098. PMID: 28694272; PMCID: PMC5505455.

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017 Apr 26;357:j1550. doi: 10.1136/bmj.j1550. PMID: 28446428; PMCID: PMC5421454.

Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015 Aug;105(8):e55-63. doi: 10.2105/AJPH.2015.302664. Epub 2015 Jun 11. PMID: 26066931; PMCID: PMC4504312.

Martin SA, Chiodo LM, Bosse JD, Wilson A. The Next Stage of Buprenorphine Care for Opioid Use Disorder. Ann Intern Med. 2018 Nov 6;169(9):628-635. doi: 10.7326/M18-1652. Epub 2018 Oct 23. PMID: 30357262.

Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014 Dec;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302. PMID: 25330017; PMCID: PMC6167926.

Weinstein ZM, Gryczynski G, Cheng DM, Quinn E, Hui D, Kim HW, Labelle C, Samet JH. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program. Drug Alcohol Depend. 2018 Aug 1;189:166-171. doi: 10.1016/j.drugalcdep.2018.05.010. Epub 2018 Jun 19. PMID: 29958128; PMCID: PMC6139651.

Hailu R, Mehrotra A, Huskamp HA, Busch AB, Barnett ML. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic. JAMA Netw Open. 2023 Jan 3;6(1):e2252381. doi: 10.1001/jamanetworkopen.2022.52381. PMID: 36692880; PMCID: PMC10038015.

In the AMA Ed Hub, satisfy the new, one-time eight-hour training requirement issued by the Drug Enforcement Administration (DEA) to meet the conditions of the MATE Act for all registered practitioners on treating and managing patients with opioid or other substance use disorders. CME activities listed on this page can be taken in any combination to fulfill the eight-hour requirement.

PCSS is a program funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) created in response to the opioid overdose epidemic to train primary care providers in the evidence-based prevention and treatment of opioid use disorders (OUD) and treatment of chronic pain.